Last Modified: February 3, 2012
Outcomes for women with metastatic breast cancer can be improved by the effective use of biomarkers and genomic assays to quantify individual risk and guide treatment selection. This continuing medical education activity will enhance the ability of oncologists to develop optimal treatment plans while integrating the latest clinical evidence into practice, ultimately improving outcomes in MBC.
Apr 9, 2012 - Use of belagenpumatucel-L, a therapeutic vaccine comprised of four tumor growth factor-β2 antisense gene-modified allogeneic non-small-cell lung cancer (NSCLC) cell lines, is associated with encouraging long-term survival for patients with stage IIIB and IV NSCLC, according to a study presented at the annual meeting of the American Association for Cancer Research, held from March 31 to April 4 in Chicago.
Jan 12, 2012